title: Pulmonary hypertension trials: current end points are flawed, but what are the alternatives?
authors.forename: Kari
authors.initials: K
authors.lastname: Roberts
authors.forename: Ioana
authors.initials: I
authors.lastname: Preston
authors.forename: Nicholas S
authors.initials: NS
authors.lastname: Hill
mesh_terms: D000203:Activities of Daily Living / Q000145:classification; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002423:Cause of Death; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000008:administration & dosage*; D005080:Exercise Test / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D011464:Epoprostenol